Headlines about GenMark Diagnostics (NASDAQ:GNMK) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. GenMark Diagnostics earned a news impact score of 0.07 on Accern’s scale. Accern also assigned news articles about the medical equipment provider an impact score of 46.2147045724245 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of equities research analysts have weighed in on GNMK shares. Zacks Investment Research upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, December 11th. BidaskClub upgraded GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 24th. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of GenMark Diagnostics in a research report on Friday, January 19th. BTIG Research set a $11.00 price target on GenMark Diagnostics and gave the company a “buy” rating in a report on Tuesday, January 16th. Finally, Canaccord Genuity dropped their price target on GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $10.60.
Shares of NASDAQ GNMK traded up $0.28 during trading on Thursday, hitting $5.46. The company had a trading volume of 170,347 shares, compared to its average volume of 423,578. The stock has a market capitalization of $276.94, a P/E ratio of -4.51 and a beta of 0.60. GenMark Diagnostics has a 52 week low of $3.63 and a 52 week high of $13.67. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.04 and a current ratio of 3.44.
In other GenMark Diagnostics news, insider Hany Massarany sold 6,584 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $4.37, for a total transaction of $28,772.08. Following the sale, the insider now directly owns 357,190 shares of the company’s stock, valued at approximately $1,560,920.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott Mendel sold 6,275 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $4.17, for a total transaction of $26,166.75. Following the sale, the chief financial officer now directly owns 246,161 shares in the company, valued at $1,026,491.37. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,164 shares of company stock worth $217,957. Company insiders own 7.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “GenMark Diagnostics (GNMK) Receives Daily Media Sentiment Score of 0.07” was originally published by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://baseballnewssource.com/2018/04/05/genmark-diagnostics-gnmk-receiving-somewhat-positive-press-coverage-study-finds/2028757.html.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.